A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

Phase 2 Not yet recruiting 165 enrolled Premier Research Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab

NaSingle-groupOpen-labelPrevention

Summary

This is a multicenter, open-label, Phase 2b study to evaluate the efficacy and safety of 2 LB SQ injections administered at a 4-month (approximately 17 weeks) interval for female contraception.

Timeline

Start: 2026-04-01
Primary completion: 2028-12-31
Completion: 2029-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	levonorgestrel butanoate	Unknown	60 mg	Subcutaneous

Indications

No indication recorded.